Form D · Pharmaceuticals
Beta Cat Pharmaceuticals, Inc.
Houston, TX · CIK 0001612655
Offering snapshot reported Jun 27, 2018 · SEC filing
- Reported sold
- $2.6M Offering amount: $6M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 12, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 27, 2018 | Initial | $2,600,000 | No comparison | 3 | SEC filing |
| Dec 18, 2017 | Initial | $1,404,918 | No comparison | 17 | SEC filing |
| Jul 2, 2015 | Initial | $1,039,561 | No comparison | 2 | SEC filing |
| Jul 8, 2014 | Initial | $500,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-315497
Source: Form D, filed Jun 27, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Rahul Aras | Executive |
| Uma Bhatt | Executive |
| Alain Cappeluti | Executive |
| Kenneth Carter | Director |
| Joe Cunningham | Director |
| Joseph Cunningham | Director |
| Casey Cunningham | Executive |
| James Eadie | Director |
| Stephen Horrigan | Executive |
| Scott Jordan | Director, Executive |
| Jonathan Northrup | Director |
| Sunil Sharma | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2450 West Holcombe Blvd
Houston, TX, 77021
Houston, TX, 77021